건선 치료 시장

Psoriasis Treatment Market- Scope of Report

TMR's report on the global Psoriasis Treatment Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the Market during the forecast period from 2025 to 2035. The report provides revenue of the global Psoriasis Treatment Market for the period 2025 to 2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Psoriasis Treatment Market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Psoriasis Treatment Market .

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Psoriasis Treatment Market .

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Psoriasis Treatment Market. These serve as valuable tools for existing Market players as well as for entities interested in participating in the global Psoriasis Treatment Market .

The report delves into the competitive landscape of the global Psoriasis Treatment Market. Key players operating in the global Psoriasis Treatment Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Psoriasis Treatment Market profiled in this report.

Key Questions Answered in Global Psoriasis Treatment Market Report:

• What are the opportunities in the global Psoriasis Treatment Market ?
• What are the major drivers, restraints, opportunities, and threats in the Market ?
• Which regional Market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2035?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the Market positions of different companies operating in the global Market ?

Psoriasis Treatment Market- Research Objectives and Research Approach

The comprehensive report on the global Psoriasis Treatment Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the Market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the Market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Psoriasis Treatment Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the Market share for each of these at the end of 2035 has been provided. Such valuable insights enable Market stakeholders in making informed business decisions for investment in the global Psoriasis Treatment Market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Psoriasis Treatment Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Psoriasis Treatment Market Analysis and Forecasts, 2020 to 2035
  • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

• 5.1. Regulatory Landscape across Key Regions / Countries
• 5.2. Psoriasis Treatment Market Trends
• 5.3. PORTER's Five Forces Analysis
• 5.4. PESTEL Analysis
• 5.5. Key Purchase Metrics for End-users
• 5.6. Brand and Pricing Analysis
• 5.7. Treatment Algorithm
• 5.8. Distributors Landscape

6. Global Psoriasis Treatment Market Analysis and Forecasts, By Drug Type

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast By Drug Type, 2020 to 2035
  • 6.3.1. Biologics
    • 6.3.1.1. TNF Inhibitors
    • 6.3.1.2. Interleukin Inhibitors
      • 6.3.1.2.1. IL-17 Inhibitors
      • 6.3.1.2.2. IL-23 Inhibitors
      • 6.3.1.2.3. Others
  • 6.3.2. Small Molecule Drugs
    • 6.3.2.1. Tyrosine kinase 2 (TYK2) inhibitors
    • 6.3.2.2. Phosphodiesterase 4 (PDE4) inhibitor
    • 6.3.2.3. Corticosteroids
    • 6.3.2.4. Retinoids
    • 6.3.2.5. Calcineurin inhibitors
    • 6.3.2.6. Others
• 6.4. Market Attractiveness By Drug Type

7. Global Psoriasis Treatment Market Analysis and Forecasts, By Type

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast By Type, 2020 to 2035
  • 7.3.1. Branded
  • 7.3.2. Generic
• 7.4. Market Attractiveness By Type

8. Global Psoriasis Treatment Market Analysis and Forecasts, By Types of Psoriasis

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast By Types of Psoriasis, 2020 to 2035
  • 8.3.1. Plaque Psoriasis
  • 8.3.2. Inverse Psoriasis
  • 8.3.3. Guttate Psoriasis
  • 8.3.4. Pustular Psoriasis
  • 8.3.5. Others
• 8.4. Market Attractiveness By Types of Psoriasis

9. Global Psoriasis Treatment Market Analysis and Forecasts, By Route of Administration

• 9.1. Introduction & Definition
• 9.2. Key Findings / Developments
• 9.3. Market Value Forecast By Route of Administration, 2020 to 2035
  • 9.3.1. Oral
  • 9.3.2. Topical
  • 9.3.3. Parenteral
• 9.4. Market Attractiveness By Route of Administration

10. Global Psoriasis Treatment Market Analysis and Forecasts, By Distribution Channel

• 10.1. Introduction & Definition
• 10.2. Key Findings / Developments
• 10.3. Market Value Forecast By Distribution Channel, 2020 to 2035
  • 10.3.1. Hospital Pharmacies
  • 10.3.2. Retail Pharmacies
  • 10.3.3. Online Pharmacies
• 10.4. Market Attractiveness By Distribution Channel

11. Global Psoriasis Treatment Market Analysis and Forecasts, By Region

• 11.1. Key Findings
• 11.2. Market Value Forecast By Region
  • 11.2.1. North America
  • 11.2.2. Europe
  • 11.2.3. Asia Pacific
  • 11.2.4. Latin America
  • 11.2.5. Middle East & Africa
• 11.3. Market Attractiveness By Region

12. North America Psoriasis Treatment Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast By Drug Type, 2020 to 2035
  • 12.2.1. Biologics
    • 12.2.1.1. TNF Inhibitors
    • 12.2.1.2. Interleukin Inhibitors
      • 12.2.1.2.1. IL-17 Inhibitors
      • 12.2.1.2.2. IL-23 Inhibitors
      • 12.2.1.2.3. Others
  • 12.2.2. Small Molecule Drugs
    • 12.2.2.1. Tyrosine kinase 2 (TYK2) inhibitors
    • 12.2.2.2. Phosphodiesterase 4 (PDE4) inhibitor
    • 12.2.2.3. Corticosteroids
    • 12.2.2.4. Retinoids
    • 12.2.2.5. Calcineurin inhibitors
    • 12.2.2.6. Others
• 12.3. Market Value Forecast By Type, 2020 to 2035
  • 12.3.1. Branded
  • 12.3.2. Generic
• 12.4. Market Value Forecast By Types of Psoriasis, 2020 to 2035
  • 12.4.1. Plaque Psoriasis
  • 12.4.2. Inverse Psoriasis
  • 12.4.3. Guttate Psoriasis
  • 12.4.4. Pustular Psoriasis
  • 12.4.5. Others
• 12.5. Market Value Forecast By Route of Administration, 2020 to 2035
  • 12.5.1. Oral
  • 12.5.2. Topical
  • 12.5.3. Topical
• 12.6. Market Value Forecast By Distribution Channel, 2020 to 2035
  • 12.6.1. Hospital Pharmacies
  • 12.6.2. Retail Pharmacies
  • 12.6.3. Online Pharmacies
• 12.7. Market Value Forecast By Country, 2020 to 2035
  • 12.7.1. U.S.
  • 12.7.2. Canada
• 12.8. Market Attractiveness Analysis
  • 12.8.1. By Drug Type
  • 12.8.2. By Type
  • 12.8.3. By Types of Psoriasis
  • 12.8.4. By Route of Administration
  • 12.8.5. By Distribution Channel
  • 12.8.6. By Country

13. Europe Psoriasis Treatment Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast By Drug Type, 2020 to 2035
  • 13.2.1. Biologics
    • 13.2.1.1. TNF Inhibitors
    • 13.2.1.2. Interleukin Inhibitors
      • 13.2.1.2.1. IL-17 Inhibitors
      • 13.2.1.2.2. IL-23 Inhibitors
      • 13.2.1.2.3. Others
  • 13.2.2. Small Molecule Drugs
    • 13.2.2.1. Tyrosine kinase 2 (TYK2) inhibitors
    • 13.2.2.2. Phosphodiesterase 4 (PDE4) inhibitor
    • 13.2.2.3. Corticosteroids
    • 13.2.2.4. Retinoids
    • 13.2.2.5. Calcineurin inhibitors
    • 13.2.2.6. Others
• 13.3. Market Value Forecast By Type, 2020 to 2035
  • 13.3.1. Branded
  • 13.3.2. Generic
• 13.4. Market Value Forecast By Types of Psoriasis, 2020 to 2035
  • 13.4.1. Plaque Psoriasis
  • 13.4.2. Inverse Psoriasis
  • 13.4.3. Guttate Psoriasis
  • 13.4.4. Pustular Psoriasis
  • 13.4.5. Others
• 13.5. Market Value Forecast By Route of Administration, 2020 to 2035
  • 13.5.1. Oral
  • 13.5.2. Topical
  • 13.5.3. Topical
• 13.6. Market Value Forecast By Distribution Channel, 2020 to 2035
  • 13.6.1. Hospital Pharmacies
  • 13.6.2. Retail Pharmacies
  • 13.6.3. Online Pharmacies
• 13.7. Market Value Forecast By Country/Sub-region, 2020 to 2035
  • 13.7.1. Germany
  • 13.7.2. U.K.
  • 13.7.3. France
  • 13.7.4. Italy
  • 13.7.5. Spain
  • 13.7.6. Switzerland
  • 13.7.7. The Netherlands
  • 13.7.8. Rest of Europe
• 13.8. Market Attractiveness Analysis
  • 13.8.1. By Drug Type
  • 13.8.2. By Type
  • 13.8.3. By Types of Psoriasis
  • 13.8.4. By Route of Administration
  • 13.8.5. By Distribution Channel
  • 13.8.6. By Country/Sub-region

14. Asia Pacific Psoriasis Treatment Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast By Drug Type, 2020 to 2035
  • 14.2.1. Biologics
    • 14.2.1.1. TNF Inhibitors
    • 14.2.1.2. Interleukin Inhibitors
      • 14.2.1.2.1. IL-17 Inhibitors
      • 14.2.1.2.2. IL-23 Inhibitors
      • 14.2.1.2.3. Others
  • 14.2.2. Small Molecule Drugs
    • 14.2.2.1. Tyrosine kinase 2 (TYK2) inhibitors
    • 14.2.2.2. Phosphodiesterase 4 (PDE4) inhibitor
    • 14.2.2.3. Corticosteroids
    • 14.2.2.4. Retinoids
    • 14.2.2.5. Calcineurin inhibitors
    • 14.2.2.6. Others
• 14.3. Market Value Forecast By Type, 2020 to 2035
  • 14.3.1. Branded
  • 14.3.2. Generic
• 14.4. Market Value Forecast By Types of Psoriasis, 2020 to 2035
  • 14.4.1. Plaque Psoriasis
  • 14.4.2. Inverse Psoriasis
  • 14.4.3. Guttate Psoriasis
  • 14.4.4. Pustular Psoriasis
  • 14.4.5. Others
• 14.5. Market Value Forecast By Route of Administration, 2020 to 2035
  • 14.5.1. Oral
  • 14.5.2. Topical
  • 14.5.3. Topical
• 14.6. Market Value Forecast By Distribution Channel, 2020 to 2035
  • 14.6.1. Hospital Pharmacies
  • 14.6.2. Retail Pharmacies
  • 14.6.3. Online Pharmacies
• 14.7. Market Value Forecast By Country/Sub-region, 2020 to 2035
  • 14.7.1. China
  • 14.7.2. Japan
  • 14.7.3. India
  • 14.7.4. Australia & New Zealand
  • 14.7.5. South Korea
  • 14.7.6. Rest of Asia Pacific
• 14.8. Market Attractiveness Analysis
  • 14.8.1. By Drug Type
  • 14.8.2. By Type
  • 14.8.3. By Types of Psoriasis
  • 14.8.4. By Route of Administration
  • 14.8.5. By Distribution Channel
  • 14.8.6. By Country/Sub-region

15. Latin America Psoriasis Treatment Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast By Drug Type, 2020 to 2035
  • 15.2.1. Biologics
    • 15.2.1.1. TNF Inhibitors
    • 15.2.1.2. Interleukin Inhibitors
      • 15.2.1.2.1. IL-17 Inhibitors
      • 15.2.1.2.2. IL-23 Inhibitors
      • 15.2.1.2.3. Others
  • 15.2.2. Small Molecule Drugs
    • 15.2.2.1. Tyrosine kinase 2 (TYK2) inhibitors
    • 15.2.2.2. Phosphodiesterase 4 (PDE4) inhibitor
    • 15.2.2.3. Corticosteroids
    • 15.2.2.4. Retinoids
    • 15.2.2.5. Calcineurin inhibitors
    • 15.2.2.6. Others
• 15.3. Market Value Forecast By Type, 2020 to 2035
  • 15.3.1. Branded
  • 15.3.2. Generic
• 15.4. Market Value Forecast By Types of Psoriasis, 2020 to 2035
  • 15.4.1. Plaque Psoriasis
  • 15.4.2. Inverse Psoriasis
  • 15.4.3. Guttate Psoriasis
  • 15.4.4. Pustular Psoriasis
  • 15.4.5. Others
• 15.5. Market Value Forecast By Route of Administration, 2020 to 2035
  • 15.5.1. Oral
  • 15.5.2. Topical
  • 15.5.3. Topical
• 15.6. Market Value Forecast By Distribution Channel, 2020 to 2035
  • 15.6.1. Hospital Pharmacies
  • 15.6.2. Retail Pharmacies
  • 15.6.3. Online Pharmacies
• 15.7. Market Value Forecast By Country/Sub-region, 2020 to 2035
  • 15.7.1. Brazil
  • 15.7.2. Mexico
  • 15.7.3. Argentina
  • 15.7.4. Rest of Latin America
• 15.8. Market Attractiveness Analysis
  • 15.8.1. By Drug Type
  • 15.8.2. By Type
  • 15.8.3. By Types of Psoriasis
  • 15.8.4. By Route of Administration
  • 15.8.5. By Distribution Channel
  • 15.8.6. By Country/Sub-region

16. Middle East & Africa Psoriasis Treatment Market Analysis and Forecast

• 16.1. Introduction
  • 16.1.1. Key Findings
• 16.2. Market Value Forecast By Drug Type, 2020 to 2035
  • 16.2.1. Biologics
    • 16.2.1.1. TNF Inhibitors
    • 16.2.1.2. Interleukin Inhibitors
      • 16.2.1.2.1. IL-17 Inhibitors
      • 16.2.1.2.2. IL-23 Inhibitors
      • 16.2.1.2.3. Others
  • 16.2.2. Small Molecule Drugs
    • 16.2.2.1. Tyrosine kinase 2 (TYK2) inhibitors
    • 16.2.2.2. Phosphodiesterase 4 (PDE4) inhibitor
    • 16.2.2.3. Corticosteroids
    • 16.2.2.4. Retinoids
    • 16.2.2.5. Calcineurin inhibitors
    • 16.2.2.6. Others
• 16.3. Market Value Forecast By Type, 2020 to 2035
  • 16.3.1. Branded
  • 16.3.2. Generic
• 16.4. Market Value Forecast By Types of Psoriasis, 2020 to 2035
  • 16.4.1. Plaque Psoriasis
  • 16.4.2. Inverse Psoriasis
  • 16.4.3. Guttate Psoriasis
  • 16.4.4. Pustular Psoriasis
  • 16.4.5. Others
• 16.5. Market Value Forecast By Route of Administration, 2020 to 2035
  • 16.5.1. Oral
  • 16.5.2. Topical
  • 16.5.3. Topical
• 16.6. Market Value Forecast By Distribution Channel, 2020 to 2035
  • 16.6.1. Hospital Pharmacies
  • 16.6.2. Retail Pharmacies
  • 16.6.3. Online Pharmacies
• 16.7. Market Value Forecast By Country/Sub-region, 2020 to 2035
  • 16.7.1. GCC Countries
  • 16.7.2. South Africa
  • 16.7.3. Rest of Middle East & Africa
• 16.8. Market Attractiveness Analysis
  • 16.8.1. By Drug Type
  • 16.8.2. By Type
  • 16.8.3. By Types of Psoriasis
  • 16.8.4. By Route of Administration
  • 16.8.5. By Distribution Channel
  • 16.8.6. By Country/Sub-region

17. Competition Landscape

• 17.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 17.2. Market Share Analysis By Company (2024)
• 17.3. Company Profiles
  • 17.3.1. Bristol-Myers Squibb Company
    • 17.3.1.1. Company Overview
    • 17.3.1.2. Financial Overview
    • 17.3.1.3. Product Portfolio
    • 17.3.1.4. Business Strategies
    • 17.3.1.5. Recent Developments
  • 17.3.2. AbbVie Inc
    • 17.3.2.1. Company Overview
    • 17.3.2.2. Financial Overview
    • 17.3.2.3. Product Portfolio
    • 17.3.2.4. Business Strategies
    • 17.3.2.5. Recent Developments
  • 17.3.3. Amgen Inc
    • 17.3.3.1. Company Overview
    • 17.3.3.2. Financial Overview
    • 17.3.3.3. Product Portfolio
    • 17.3.3.4. Business Strategies
    • 17.3.3.5. Recent Developments
  • 17.3.4. AstraZeneca
    • 17.3.4.1. Company Overview
    • 17.3.4.2. Financial Overview
    • 17.3.4.3. Product Portfolio
    • 17.3.4.4. Business Strategies
    • 17.3.4.5. Recent Developments
  • 17.3.5. Eli Lilly and Company
    • 17.3.5.1. Company Overview
    • 17.3.5.2. Financial Overview
    • 17.3.5.3. Product Portfolio
    • 17.3.5.4. Business Strategies
    • 17.3.5.5. Recent Developments
  • 17.3.6. Johnson & Johnson Services, Inc.
    • 17.3.6.1. Company Overview
    • 17.3.6.2. Financial Overview
    • 17.3.6.3. Product Portfolio
    • 17.3.6.4. Business Strategies
    • 17.3.6.5. Recent Developments
  • 17.3.7. LEO Pharma A/S
    • 17.3.7.1. Company Overview
    • 17.3.7.2. Financial Overview
    • 17.3.7.3. Product Portfolio
    • 17.3.7.4. Business Strategies
    • 17.3.7.5. Recent Developments
  • 17.3.8. Merck & Co., Inc.,
    • 17.3.8.1. Company Overview
    • 17.3.8.2. Financial Overview
    • 17.3.8.3. Product Portfolio
    • 17.3.8.4. Business Strategies
    • 17.3.8.5. Recent Developments
  • 17.3.9. Novartis AG
    • 17.3.9.1. Company Overview
    • 17.3.9.2. Financial Overview
    • 17.3.9.3. Product Portfolio
    • 17.3.9.4. Business Strategies
    • 17.3.9.5. Recent Developments
  • 17.3.10. Boehringer Ingelheim Pharmaceuticals, Inc.
    • 17.3.10.1. Company Overview
    • 17.3.10.2. Financial Overview
    • 17.3.10.3. Product Portfolio
    • 17.3.10.4. Business Strategies
    • 17.3.10.5. Recent Developments
  • 17.3.11. Arcutis Biotherapeutics, Inc
    • 17.3.11.1. Company Overview
    • 17.3.11.2. Financial Overview
    • 17.3.11.3. Product Portfolio
    • 17.3.11.4. Business Strategies
    • 17.3.11.5. Recent Developments
  • 17.3.12. Dermavant Sciences, Inc.
    • 17.3.12.1. Company Overview
    • 17.3.12.2. Financial Overview
    • 17.3.12.3. Product Portfolio
    • 17.3.12.4. Business Strategies
    • 17.3.12.5. Recent Developments
  • 17.3.13. TIEFENBACHER GROUP
    • 17.3.13.1. Company Overview
    • 17.3.13.2. Financial Overview
    • 17.3.13.3. Product Portfolio
    • 17.3.13.4. Business Strategies
    • 17.3.13.5. Recent Developments
  • 17.3.14. UCB S.A.
    • 17.3.14.1. Company Overview
    • 17.3.14.2. Financial Overview
    • 17.3.14.3. Product Portfolio
    • 17.3.14.4. Business Strategies
    • 17.3.14.5. Recent Developments
  • 17.3.15. Bausch Health
    • 17.3.15.1. Company Overview
    • 17.3.15.2. Financial Overview
    • 17.3.15.3. Product Portfolio
    • 17.3.15.4. Business Strategies
    • 17.3.15.5. Recent Developments
  • 17.3.16. Sun Pharmaceutical Industries Limited
    • 17.3.16.1. Company Overview
    • 17.3.16.2. Financial Overview
    • 17.3.16.3. Product Portfolio
    • 17.3.16.4. Business Strategies
    • 17.3.16.5. Recent Developments
  • 17.3.17. Akeso Biopharma Co., Ltd.
    • 17.3.17.1. Company Overview
    • 17.3.17.2. Financial Overview
    • 17.3.17.3. Product Portfolio
    • 17.3.17.4. Business Strategies
    • 17.3.17.5. Recent Developments